2015 Fiscal Year Final Research Report
New treatment strategy against bone and soft tissue sarcoma by combination of telomerase-specific oncolytic adenovirus
| Project/Area Number |
25462333
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OZAKI Toshifumi 岡山大学, 医歯薬学総合研究科, 教授 (40294459)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | ウイルス治療 / 肉腫 |
|---|
| Outline of Final Research Achievements |
We previously developed an oncolytic adenovirus, OBP-301, in which the hTERT gene promoter drives the expression of the E1A and E1B genes. A phase I clinical trial of OBP-301 was conducted in the United States on patients with advanced solid tumors, and a phase II clinical trial is being conducted in our hospital on patients with advanced esophageal cancer. In this study, we revealed the cytopathic activity of OBP-301 in bone and soft tissue sarcoma cells. Moreover, OBP-301 enhanced chemosensitivity to doxorubicin and cisplatin in human osteosarcoma cells. The antitumor effect of OBP-301 was remarkable on human osteosarcoma orthotopic xenograft model; however, bone destruction could not be prevented by OBP-301 monotherapy. Combination treatment with OBP-301 and zoledronic acid showed a synergistic antitumor effect, and prevented bone destruction. Our data indicates that OBP-301 is a promising antitumor reagent for the treatment of bone and soft tissue sarcomas
|
| Free Research Field |
骨軟部腫瘍
|
